Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

By LabMedica International staff writers
Posted on 15 Jul 2025

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. More...

Traditional methods for evaluating myeloma treatment often require large cell samples, complex preparation, and time-intensive measurements, making it challenging to monitor individual patient responses quickly and accurately. As treatment effectiveness can vary from patient to patient, it’s crucial to assess how cancer cells are responding to therapy in real-time. Now, researchers have developed a novel method to track cancer treatment responses in individual cells without the need for dyes or labels, providing faster and more precise insights into treatment effectiveness.

The mid-infrared optoacoustic microscopy (MiROM) technology, developed by researchers from Helmholtz Munich (Munich, Germany) and the Technical University of Munich (Munich, Germany), can track treatment responses in individual cancer cells without the need for dyes or labels. This technology uses mid-infrared light to detect molecular vibrations in proteins, which helps to identify structural changes such as protein misfolding, a key indicator of myeloma treatment response.

MiROM works by capturing ultrasound waves generated when proteins absorb infrared light, causing a localized temperature increase. This approach enables real-time visualization of protein changes inside living cells, allowing for more personalized treatment of multiple myeloma patients. The researchers demonstrated MiROM’s ability to analyze individual cells with minimal sample preparation, providing fast insights into how treatments impact protein structures at the cellular level.

The MiROM technology was tested and validated by applying it to living myeloma cells. It successfully detected protein misfolding and apoptosis, or programmed cell death, which are key indicators of whether cancer treatments are working or if drug resistance is developing. Published in Lancet Healthy Longevity, the findings suggest that MiROM can provide near-instantaneous assessments of cancer treatment effectiveness, paving the way for more personalized therapy adjustments.

Beyond myeloma, MiROM shows potential for diagnosing other diseases related to protein misfolding, such as Alzheimer’s and Parkinson’s. Future research will focus on optimizing the technology for faster imaging and enhancing its sensitivity for broader clinical applications, including drug screening, diagnostics, and home-based patient monitoring.

“We envision the use of MiROM in drug screening, diagnostic tests and home-based patient monitoring,” said Prof. Vasilis Ntziachristos, a senior investigator in the study.

Related Links:
Helmholtz Munich
Technical University of Munich


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.